Anges Inc. has entered into a sponsored research agreement with Stanford University School of Medicine for the development of novel cancer therapies using genome editing technology. The parties aim to ...

It feels fantastic,” said Blau, who thanked her lab members and colleagues for their support and dedication. “This ...

The woolly mammoth has been extinct for thousands of years, but Colossal Biosciences is pursuing technology that could help bring them back.

(Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

Caribou has initiated the GALLOP Phase 1 clinical trial, an open-label, multicenter clinical trial designed to evaluate a single infusion of CB-010 in adult patients with LN and ERL. CB-011, a ...

We are excited to welcome Eric to our Board of Directors,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “His tremendous track record in the pharmaceutical industry as well as his ...

The de-extinction company led by CEO Ben Lamm has raked in $435 million in funding since its launch. He believes it has ...

Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

Colossal BioSciences has raised $200 million in a new round of funding to bring back extinct species like the woolly mammoth.

In BlueAllele Corp. v. Intellia Therapeutics, Inc., 2024 U.S. Dist. Lexis 222094 (D. Del. Dec. 9, 2024)1, the District of ...

Colossal Biosciences, the world’s first company dedicated to bringing back animals from extinction, has secured $200 million ...